AN ASSESSMENT OF THE SERIOUS INFECTION RATE IN RITUXIMAB-TREATED RHEUMATOID ARTHRITIS (RA) PATIENTS WHO SUBSEQUENTLY RECEIVED OTHER BIOLOGIC THERAPIES: A FOLLOW-UP FROM RITUXIMAB CLINICAL TRIALS

被引：0
|
作者：
Genovese, Mark C. [1 ]
Breedveld, Ferdinand C. [2 ]
Emery, Paul [3 ]
Cohen, Stanley B. [4 ]
Keystone, Edward C. [5 ]
Matteson, Eric L. [6 ]
Burke, Laura S. [7 ]
Chai, Akiko
Reiss, William G. [8 ]
Sweetser, Marianne T. [9 ]
Shaw, Tim M. [10 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Leiden Univ, Leiden, Netherlands
[3] Chapel Allerton Hosp, Leeds, W Yorkshire, England
[4] Metroplex Clin Res Ctr, Dallas, TX USA
[5] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[6] Mayo Clin, Rochester, MN USA
[7] Roche Inc, Welwyn Garden City, Herts, England
[8] Genentech Inc, Clin Dev, San Francisco, CA 94080 USA
[9] Biogen Idec Inc, Drug Safety, Cambridge, MA USA
[10] Roche Ltd, Clin Sci Inflamm, Welwyn Garden City, Herts, England
来源：
RHEUMATOLOGY | 2010年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：I4 / I4
页数：1
相关论文
共 25 条
  • [1] Assessing the Rate of Serious Infections in Rheumatoid Arthritis (RA) Patients who Receive Other Biologic Therapies after Discontinuing Rituximab (RTX)
    Genovese, M.
    Cividino, A.
    Keystone, E.
    Breedveld, F.
    Emery, P.
    Cohen, S.
    Matteson, E.
    Burke, L.
    Chai, A.
    Reiss, W.
    Sweetser, M.
    Shaw, T.
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (06) : 1165 - 1165
  • [2] LONG-TERM SAFETY OF RITUXIMAB: FOLLOW-UP OF THE RHEUMATOID ARTHRITIS CLINICAL TRIALS AND RETREATMENT POPULATION
    Van Vollenhoven, R.
    Littlejohn, G.
    Emery, P.
    Bingham, C.
    Keystone, E.
    Fleischmann, R.
    Furst, D.
    Jones, G.
    Tyson, N.
    Collinson, N.
    Lehane, P.
    INTERNAL MEDICINE JOURNAL, 2011, 41 : 18 - 18
  • [3] Long Term Safety of Rituximab in Rheumatoid Arthritis Clinical Trials: A 10-Year Follow-Up Study
    Keystone, Edward
    Emery, Paul
    Bingham, Clifton
    Maldonado, Michael
    Furst, Daniel
    Tyson, Nicola
    Mehbob, Abdul
    Lehane, Patricia
    van Vollenhoven, Ronald
    Haraoui, Boulos
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1442 - 1442
  • [4] Long-Term Safety of Rituximab: 6-year Follow-up of the Rheumatoid Arthritis (RA) Clinical Trials and Re-treatment Population
    Pope, Janet
    van Vollenhoven, Ronald F.
    Emery, Paul
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2603 - 2603
  • [5] Long-term safety data from extended follow-up and repeat use of Rituximab (RTX) in patients with active rheumatoid arthritis (RA)
    Ronald, Van Vollenhoven
    Tore, Kvien
    Jean, Sibilia
    Paul, Emery
    Clifton, Bingham
    Edward, Keystone
    Maria, Greenwald
    Larry, Moreland
    Marrianne, Sweetser
    Karen, Rowe
    Bridget, Wagner
    Fabio, Magrini
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 : 51 - 51
  • [6] LONG-TERM SAFETY OF RITUXIMAB IN RHEUMATOID ARTHRITIS: LONG-TERM FOLLOW-UP OF CLINICAL TRIALS AND RETREATMENT POPULATION
    van Vollenhoven, Ronald F.
    Emery, Paul
    Bingham, Clifton O.
    Keystone, Edward C.
    Fleischmann, Roy M.
    Furst, Daniel E.
    Macey, Katherine
    Sweetster, Marianne T.
    Lehane, Patricia B.
    Farmer, Pamela
    Long, Simon G.
    RHEUMATOLOGY, 2010, 49 : I104 - I104
  • [7] Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis (RA): Results from the dose-ranging assessment international clinical evaluation of rituximab in RA (dancer) study
    Van Vollenhoven, R
    Emery, R
    Fleischmann, RM
    Filipowicz-Sosnowska, A
    Szczepanski, L
    Racewicz, A
    Schechtman, J
    Rowe, KA
    Tyrrell, H
    Li, NF
    Sewell, KL
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 432 - 432
  • [8] Safety data from 48 weeks follow-up of a randomised controlled trial of rituximab in patients with rheumatoid arthritis.
    Szczepanski, L
    Szechinski, J
    Filipowicz-Sosnowska, A
    Emery, P
    Edwards, JCW
    Magrini, F
    Lehane, PB
    Shaw, TM
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S121 - S121
  • [9] Prospective follow-up of rituximab treatment in 965 patients with refractory rheumatoid arthritis (630 patients/year):: Tolerance and efficacy data from the french registry air (autoimmunity and rituximab)
    Gottenberg, Jacques-Eric
    Ravaud, Philippe
    Bardin, Thomas
    Combe, Bernard
    Dougados, Maxime
    Le Loet, Xavier
    Sibilia, Jean
    Taburet, Anne-Marie
    Baron, Gabriel
    Lupo, Geraldine
    Mariette, Xavier
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S611 - S611
  • [10] Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
    Chatzidionysiou, Katerina
    Lie, Elisabeth
    Nasonov, Evgeny
    Lukina, Galina
    Hetland, Merete Lund
    Tarp, Ulrik
    van Riel, Piet L. C. M.
    Nordstrom, Dan C.
    Gomez-Reino, Juan
    Pavelka, Karel
    Tomsic, Matija
    Kvien, Tore K.
    van Vollenhoven, Ronald F.
    Gabay, Cem
    ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (03) : 374 - 377
123